Suche
Mein Konto
Revolutionary therapy: New CE approval for liver cancer treatment!
Sirtex Medical Receives Expanded CE Approval for Y-90 Resin Microspheres to Treat Liver Cancer, Improve Patient Care.
Revolutionary therapy: New CE approval for liver cancer treatment!
The medical landscape for patients with liver cancer has taken an encouraging turn. On September 9, 2025, Sirtex Medical received extended CE approval for its SIR-Spheres® Y-90 resin microspheres. This innovative therapy is now not only aimed at patients with unresectable hepatocellular carcinoma (HCC), but also includes primary liver carcinomas and secondary liver metastases. The focus is on increasing access to this proven, targeted treatment that allows precise irradiation of the tumor without damaging healthy tissue. Prnewswire reports that the decision is based on a thorough review of the clinical data on the safety and effectiveness of SIR-Spheres®.
Radioembolization (SIRT), which is used in this procedure, has few complications compared to other therapies as long as patients are carefully selected and pretreated. Patients with preserved liver functions, a Child-Pugh score of less than 7 and no signs of ascites or encephalopathy are ideal. Loud PMC Side effects are usually mild and include symptoms such as abdominal pain and nausea after treatment, known as postradioembolization syndrome. Serious complications are rare.
The role of Sirtex Medical
Sirtex Medical specializes in minimally invasive, liver-targeted cancer and embolization therapies. With offices in the US, Australia, Europe and Asia, the company plays an essential role in the global healthcare sector. Prof. Dr. Jens Ricke highlights the clinical value of Y-90 radioembolization, especially in complex liver tumors. The FDA also approved SIR-Spheres for the treatment of unresectable HCC in the United States, furthering the therapy's international recognition.
Future perspectives and research
While interest in radioembolization is growing among professionals, various clinical trials are underway to further investigate the effectiveness of this therapy. In particular, ongoing phase II/III trials are active evaluating the combination of radioembolization with systemic therapies for advanced HCC and metastatic liver disease. These developments are of great importance as there are currently not many randomized controlled trials on this promising approach.
Overall, it shows that Sirtex Medical's renewed CE approval not only represents progress for patients, but also strengthens trust in radioembolization as a novel therapeutic option. The development and dissemination of such therapies could help to significantly improve treatment outcomes for liver cancer.